Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Rules, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill aims to boost innovation in Medicare and Medicaid programs through new policies.
The problem
Medicare and Medicaid may not quickly adopt new medical technologies and innovations. Slower adoption can limit patient access to modern treatments and improvements.
The proposal
The bill likely encourages faster approval and use of new medical technologies in Medicare and Medicaid. Specific mechanisms unknown due to lack of official summary.
The impact
Medicare and Medicaid patients, healthcare providers, drug/device manufacturers, and taxpayers. Changes may affect treatment access, program costs, and innovation investment.
Patients may get newer treatments and technologies sooner through Medicare and Medicaid. This could improve health outcomes for seniors and low-income beneficiaries. Faster adoption means less waiting for proven innovations.
Clear pathways for new products may attract more investment in medical research. Companies have stronger incentives to develop solutions for Medicare and Medicaid patients. This can create better treatment options overall.
U.S. companies may lead in medical innovation globally. Faster U.S. adoption of new technologies strengthens American healthcare leadership and competitiveness internationally.
Innovation in healthcare can create jobs and grow the medical technology sector. New companies and research facilities may expand, benefiting local economies.
Newer treatments and technologies often cost more than established ones. Faster adoption could increase Medicare and Medicaid spending significantly. Taxpayers may face higher costs.
Rushing adoption without thorough testing could expose patients to unproven treatments. Side effects or effectiveness issues might emerge later. Patient safety could be compromised.
If private insurance gets new technologies first, Medicare and Medicaid patients may still wait. This could widen healthcare gaps between wealthy and poor patients.
Not all innovations prove better in real-world use. Adopting unproven technologies could waste taxpayer money on ineffective treatments. Resources might be better spent elsewhere.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
No donor data found for current cycle
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.